U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                  FORM 10-QSB


[X]  QUARTERLY  REPORT  UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF  1934  for  the  quarterly  period  ended  September  30,  2004

[ ]  TRANSITION  REPORT  UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT  OF  1934  for  the  transition  period  from  _______  to  _______


                         PINGCHUAN PHARMACEUTICAL, INC.
                         ------------------------------
        (Exact name of small business issuer as specified in its charter)


                                 XENICENT, INC.
                                 --------------
                     (former name of small business issuer)


         North  Carolina                                  36-4344865
         ---------------                                  ----------
(State  or  other  jurisdiction  of            (IRS Employer Identification No.)
  incorporation  or  organization)


                32 Ganshui Rd., Harbin, Heilongjiang, P.R.China
                -----------------------------------------------
                    (Address of principal executive offices)


                                (86451) 8271-3712
                                -----------------
                          (Issuer's telephone number)


Check  whether  the issuer (1) filed all reports required to be filed by Section
13  or  15(d) of the Exchange Act during the past 12 months (or for such shorter
period  that the registrant was required to file such reports), and (2) has been
subject  to  such  filing  requirements  for  the  past 90 days. Yes [x] No [  ]

Number  of  shares  of  common  stock  outstanding  as  of
November  18,  2004:  70,842,407

Number  of  shares  of  preferred  stock  outstanding  as  of
November  18,  2004:  -0-


                              INDEX TO FORM 10-QSB

                                                                       Page  No.
                                                                       ---------
PART  I
-------

Item  1.  Financial  Statements  -  Unaudited

          Condensed  Balance  Sheet  -  September  30, 2004                    3

          Condensed  Statements  of  Operations  - Three Months
          and Nine Months Ended September  30,  2004  and  2003                4

          Condensed Statements of Cash Flows - Nine Months Ended
          September  30,  2004  and  2003                                      5

          Notes  to  Condensed  Unaudited  Financial  Statements             6-7

Item  2.  Management's Discussion and Analysis of Financial
          Condition  And  Results  of  Operations                              8

Item  3.  Quantitative and Qualitative Disclosures on Market Risk             14

Item  4.  Controls and Procedures                                             15

PART II
-------

Item  1.  Legal  Proceedings                                                  15

Item  2.  Changes in Securities                                               15

Item  3.  Defaults  Upon  Senior  Securities                                  15

Item  4.  Submission  of  Matters  to  a  Vote  of  Security  Holders         15

Item  5.  Other  Information                                                  15

Item  6.  Exhibits                                                         16-18


                 PING CHUAN PHARMACEUTICAL, INC. AND SUBSIDIARY
                           CONSOLIDATED BALANCE SHEET
                         SEPTEMBER 30, 2004 (UNAUDITED)
==============================================================================

                                     ASSETS

CURRENT  ASSETS:
   Cash and cash equivalents                                      $     61,700
   Receivable, other                                                     6,745
   Prepaid expenses                                                     71,144
   Due from stockholder                                                 80,000
                                                                  ------------
      TOTAL CURRENT ASSETS                                             219,589
                                                                  ------------

OTHER ASSETS:                                                                -
                                                                  ------------

      TOTAL ASSETS                                                $    219,589
                                                                  ============


                      LIABILITIES AND STOCKHOLDERS' EQUITY
                      ------------------------------------

CURRENT  LIABILITIES:
   Other payables and accrued expenses                                  14,587
   Accrued taxes                                                         5,492
   Convertible notes payable                                            80,000
                                                                  ------------
      TOTAL CURRENT LIABILITIES                                        100,079
                                                                  ------------

STOCKHOLDERS'  EQUITY:
   Preferred stock ($.001 par value, 5,000,000 shares
   authorized: none issued and outstanding)                                  -
   Common stock ($.001 par value, 150,000,000 shares authorized:
   70,842,407 issued and outstanding)                                   70,842
   Common stock to be returned ($.001 par value,
   110,000 common shares)                                                 (110)
   Additional paid-in-capital                                           50,047
   Accumulated deficit                                                  (1,269)
                                                                  ------------
      TOTAL STOCKHOLDERS' EQUITY                                       119,510
                                                                  ------------

      TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                  $    219,589
                                                                  ============


The  accompanying  notes  are  an  integral  part  of these financial statements


<TABLE>
<CAPTION>

                            PING CHUAN PHARMACEUTICAL, INC. AND SUBSIDIARY
                                 CONSOLIDATED STATEMENTS OF OPERATIONS
                FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2004 AND 2003 (UNAUDITED)
===============================================================================================================

                                          Three Months Ended September 30,       Nine Months Ended September 30,
                                              2004                2003               2004              2003
                                          ------------        ------------       ------------      ------------
<S>                                       <C>                 <C>                <C>               <C>

REVENUE  AND  COST  OF  SALES:
   Sales                                  $          -        $          -       $          -      $    118,032
   Cost of sales                                     -                   -                  -           115,075
   Taxes                                             -                   -                  -               519
                                          ------------        ------------       ------------      ------------
      Gross Profit                                   -                   -                  -             2,438
                                          ------------        ------------       ------------      ------------

OPERATING  EXPENSES:

   Selling, general and administrative             586                 227              1,718               801
                                          ------------        ------------       ------------      ------------
      TOTAL EXPENSES                               586                 227              1,718               801
                                          ------------        ------------       ------------      ------------

      NET INCOME (LOSS)                   $       (586)       $       (227)      $     (1,718)     $      1,637
                                          ============        ============       ============      ============

   Basic & fully diluted loss per share          (0.00)              (0.00)             (0.00)             0.00
                                          ============        ============       ============      ============

   Weighted average common shares
   Outstanding                              70,842,407          70,842,407         70,842,407        70,842,407
                                          ============        ============       ============      ============


</TABLE>


The  accompanying  notes  are  an  integral  part  of these financial statements


<TABLE>
<CAPTION>


                           PING CHUAN PHARMACEUTICAL, INC. AND SUBSIDIARY
                                CONSOLIDATED STATEMENTS OF CASH FLOWS
                   FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2004 AND 2003 (UNAUDITED)
==========================================================================================================

                                                                                  2004            2003
                                                                              ------------    ------------
<S>                                                                           <C>             <C>

CASH  FLOWS  FROM  OPERATING  ACTIVITIES:
   Net income (loss)                                                          $     (1,718)   $      1,637
   Adjustments to reconcile net income (loss) to net
   cash provided by (used in) operating activities:
     (Increase)  decrease  in  operating  assets:
         Receivable, other                                                               3               1
         Prepaid expenses                                                          (71,144)              -
         Inventories                                                                   430         114,652
      Increase  (decrease)  in  operating  liabilities:
         Other payables and accrued expenses                                           135          12,809
         Accrued taxes                                                                  (3)          5,051
         Foreign Currency translation                                                  (64)             (8)
                                                                              ------------    ------------
         NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES                       (72,361)        134,142
                                                                              ------------    ------------

CASH FLOWS FROM INVESTING ACTIVITIES:                                                    -               -
                                                                              ------------    ------------

CASH FLOWS FROM FINANCING ACTIVITIES:                                                    -               -
                                                                              ------------    ------------

         NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                      (72,361)        134,142

CASH AND CASH EQUIVALENTS:
   Beginning of year                                                               134,061             145
                                                                              ------------    ------------

   End of period                                                              $     61,700    $    134,287
                                                                              ============    ============

SUPPLEMENTAL  CASH  FLOW  DISCLOSURES  AND  NON-CASH
INVESTING  INFORMATION:
   Common stock issued to others for services                                 $          -    $          -
                                                                              ============    ============
   Cash paid during the year for interest                                     $          -    $          -
                                                                              ============    ============


</TABLE>


The  accompanying  notes  are  an  integral  part  of these financial statements



                  PINGCHUAN PHARMACEUTICAL, INC. AND SUBSIDIARY
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                         September 30, 2004 (Unaudited)

ITEM  1.
--------

NOTE  1  -  BASIS  OF  PRESENTATION

     The accompanying unaudited condensed consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the
United  States  of America for interim financial information and pursuant to the
rules  and  regulations  of the Securities and Exchange Commission. Accordingly,
they  do  not include all of the information and footnotes required by generally
accepted  accounting  principles  for  complete  financial  statements.

     In  the  opinion  of  management,  the  unaudited  condensed  consolidated
financial statements contain all adjustments consisting only of normal recurring
accruals considered necessary to present fairly the Company's financial position
at  September  30, 2004, the results of operations for the three months and nine
months  ended  September  30,  2004 and 2003, and cash flows for the nine months
ended  September  30,  2004 and 2003. The results for the period ended September
30,  2004  are  not necessarily indicative of the results to be expected for the
entire  fiscal  year ending December 31, 2004. These financial statements should
be  read in conjunction with the Company's annual report on Form 10-KSB as filed
with  the  Securities  and  Exchange  Commission.

     Use  of  estimates  -  The  preparation  of  the  financial  statements  in
conformity  with USGAAP requires  the Company's management to make estimates and
assumptions  that affect the  reports  amounts  of  assets  and  liabilities  at
the  date  of  financial  statements  and  the  reported amounts of revenues and
expenses  during  the  reported periods.  Actual amounts could differ from those
estimates.

     Earnings  (Loss)  per  share - Basic  earnings  (loss)  per  share  exclude
dilution  and  are computed by dividing loss available to common shareholders by
the  weighted  average  number of common  shares  outstanding  for  the  period.

     Diluted  earnings  per share are computed by dividing earnings available to
common  shareholders by the weighted average number of common shares outstanding
adjusted  to  reflect potentially dilutive securities. The company does not have
any  dilutive  securities  outstanding  as  of  September  30,  2004.

NOTE  2  -  REORGANIZATION  AND  STOCKHOLDERS'  EQUITY

     On  July  28,  2004, Xenicent changed its name to Pingchuan Pharmaceutical,
Inc.  ("PGCN")  and  increased  its  authorized  shares  of  common  stock  from
50,000,000  to 150,000,000 by filing Articles of Amendment with the Secretary of
State  of  the  State  of  North  Carolina.  In addition, on August 3, 2004, the
Over-the-Counter  Bulletin Board awarded the new trading symbol of "PGCN" to the
Company.

     On  August 11, 2004, Pingchuan Pharmaceutical, Inc. ("PGCN") consummated an
agreement  with  Heilongjiang  Pingchuan  Yi Liao Qi Xie You Xian Gong Si ("Ping
Chuan")  a  corporation  organized  and  existing under the laws of the Peoples'
Republic  of  China,  pursuant  to  which Ping Chuan exchanged its 1,000,000 RMB
capital  ($120,779)  for 70,000,000 shares of common stock of PGCN. In addition,
Ping  Chuan paid $400,000 to a PGCN shareholder to purchase and retire 1,300,000
shares  PGCN  common  stock.  The PGCN shareholder received $320,000 in cash and
notes  for  $80,000  in  satisfaction  of the purchase price. As a result of the
agreement,  the  transaction  was  treated  for  accounting  purposes  as  a
reorganization by the accounting acquirer (Ping Chuan) and as a recapitalization
by  the  accounting  acquiree  (PGCN).

NOTE  3  -  RELATED  PARTY  TRANSACTIONS

     Due from stockholders, $80,000 represents amounts due from stockholders for
payments  on  $80,000  convertible  notes  (See  Note  4).

NOTE  4  -  CONVERTIBLE  NOTES  PAYABLE

     The  $  80,000  notes  payable (two $40,000 each) represents principle of $
36,700  and accrued interest of $ 3,300, each note, or approximately 9% interest
per  annum.  The  notes are to be paid in twelve monthly installments of $ 1,000
each. The balance of $ 28,000, each note, due and payable on August 25, 2005 may
be  paid,  at  the  option of the Company, in cash or in an equivalent amount of
Ping  Chuan  Pharmaceutical,  Inc. stock, determined by the bid price on the OTC
Bulletin  Board  on  the  date  of  issuance  of  such  stock.

NOTE  5  -  GOING  CONCERN  CONSIDERATION

     The Company has suffered a loss, has negative cash flows from operations of
$72,361  and  has  an accumulated deficit of $1,269 on September 30, 2004. These
factors  raise  substantial  doubt  about the Company's ability to continue as a
going  concern.  The Company's continued existence is dependent upon its ability
to  resolve  its  business  and  liquidity problems, principally through raising
additional  capital  and increasing its sales. Management's plans with regard to
this matter are to seek additional capital for operations through either debt or
equity  and  enact  a  business  combination. The merger with Ping Chuan is also
intended  to  address  this  situation.

ITEM  2.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OR  PLAN  OF  OPERATION
--------

     With the exception of historical facts stated herein, the matters discussed
in  this  report  are  "forward  looking"  statements  that  involve  risks  and
uncertainties  that  could  cause  actual  results  to  differ  materially  from
projected  results.  Such  "forward  looking"  statements  include,  but are not
necessarily  limited  to,  statements  regarding  anticipated  levels  of future
revenues and earnings from operations of the Company. Readers of this report are
cautioned  not to put undue reliance on "forward looking" statements, which are,
by  their  nature,  uncertain  as reliable indicators of future performance. The
Company  disclaims  any  intent  or obligation to publicly update these "forward
looking"  statements,  whether as a result of new information, future events, or
otherwise.  In  addition  the  uncertainties  include,  but  are not limited to,
competitive  conditions  involving  the  Company's  markets.

GENERAL  DESCRIPTION  OF  BUSINESS
----------------------------------

     We  were  incorporated  in  North  Carolina  on July 26, 1996 as Great Land
Development Co. We changed our name to Xenicent, Inc. on November 8, 2000. Since
our incorporation as Great Land Development Co., we have engaged in the business
of  real  estate  consulting and purchasing and reselling vacant tracts of land,
primarily  in  the  North  Carolina  area.

     On  July  28,  2004, our name was changed to Pingchuan Pharmaceutical, Inc.
pursuant  to the plan of exchange with Heilongjiang Pingchuan Yi Liao Qi Xie You
Xian Gong Si ("Ping Chuan"), a corporation organized and existing under the laws
of  the Peoples' Republic of China, signed on June 22, 2004 and closed on August
11,  2004.  The  shareholders  of  Ping  Chuan  (the  "Ping Chuan Shareholders")
exchanged all of their registered capital of Ping Chuan for 70,000,000 shares of
common  stock  of  the  Company, or 98% of the Company's then outstanding common
stock.  Upon  completion  of  the  exchange,  Ping  Chuan  became a wholly-owned
subsidiary  of  the  Company  and  the  Ping  Chuan Shareholders transferred RMB
1,000,000 in registered share capital (representing US$120,779) of Ping Chuan to
the  Company.

     The  consummation  of  the  exchange transaction has had several additional
consequences.  Chairman  Duane  Bennett  filled  five  vacancies on the Board of
Directors of the Company with designees of Ping Chuan and then he resigned.  The
names  and  positions  of these individuals are:  Mr. Zhanwu Hu, Chairman of the
Board  and  President;  Mr.  Qitai Yao, Director and CEO; Mr. Yi Xiao, Director,
Vice  President  and  Vice  General  Manager;  Mr.  Xichen  Gao,  Director, Vice
President  and Vice General Manager; and Ms. Chunli Li, Director, Vice President
and  Vice  General  Manager.  Reference is made to a Current Report on Form 8-K,
dated  August  11,  2004,  filed  by  the  Company  with  the  Commission, for a
description  of the backgrounds and shareholdings of each of these directors and
officers.

     In addition, Bennett and the other founding principals of Xenicent received
the  last  of their payments of cash and notes totaling $400,000 in exchange for
tendering  their  1,300,000  shares  of  common  stock  of  the  Company  for
cancellation.

     Our  Ping  Chuan subsidiary is an integrated pharmaceutical company located
in  Harbin,  People's Republic of China, which produces antibiotics, medicine in
capsule  form,  traditional  Chinese medicine and other products. It had audited
revenue  of  approximately US$118,007 in fiscal 2003, and over 50 employees. The
audited  financial statements for the years ended December 31, 2003 and 2002 are
filed  in  an amendment of Current Report on Form 8-K/A, dated October 25, 2004.
Ping  chuan  was  established  in  2001, and its modern factory is located in an
economic  technology development zone in Harbin.  Most of Ping Chuan's employees
are  highly educated, including engineers with advances degrees, pharmacists and
college  graduates  with  bachelor  degrees.

     As  mentioned  above,  Ping  Chuan's products include antibiotics, chemical
medical  capsules  and  traditional  Chinese medicine.  Ping Chuan also produces
medical  intermediates  and  pharmaceutical  preparations,  as  well  as medical
instruments and health care food and other related products.  These products are
sold  via  nation-wide  sales  networks  in China. Ping Chuan also has an active
export  business,  particularly  to  Russia. Ping Chuan's business plan includes
raising  capital for growth in the United States capital markets. This is one of
the  major  reasons  Ping  Chuan  entered  into  the  exchange  transaction with
Xenicent,  a  company without operations that was traded on the Over-The-Counter
Bulletin  Board.
COMPETITION

     We  expect  to  encounter  intense  competition  from  other pharmaceutical
companies having a business objective similar to ours. Many of these competitors
possess  greater  financial, marketing, technical, personnel and other resources
than  us and there can be no assurances that we will have the ability to compete
successfully.  Our  financial  resources  are extremely limited in comparison to
those of many of our competitors.  Management believes, however, that our status
as  a reporting public entity with access to the U.S. capital markets could give
us  a  competitive  advantage  over  privately  held  entities  having a similar
business  objective  to  ours.

RESULTS  OF  OPERATIONS
-----------------------

Net  Income  /  Loss

     The  Company had a net loss of $1,718 from continuing operations, or $0 per
common  share, for the nine months ended September 30, 2004, versus a net income
of  $1,637,  or  $0  per  common  share,  for the same period ended in 2003. The
increase  in  net  loss  from the prior year was primarily due to an increase in
general  and administrative expenses, which was $1,718 for the nine months ended
September  30,  2004,  versus  $801  for  the  same  period  ended  in  2003.

Sales

     There  were  no  sales for the nine months ended September 30, 2004, versus
sales  revenue  of  $118,032  for  the  same  period  ended  in  2003.

Expenses

     Operating  expenses  for the nine months ended September 30, 2004 increased
to  $1,718 from $801 in the same period in 2003. An increase of $917 in selling,
general  and  administrative expenses in 2004 was due primarily to the increases
in  employees'  payroll.

Liquidity  and  Capital  Resources

     On  September 30, 2004, the Company had cash of $61,700 and working capital
surplus  of  $119,510.  The  working  capital  surplus  was due primarily to the
prepaid  expense,  which  was  $71,144  on  September  30,  2004.

     Net  cash  flows  used  in operating activities were $(72,361) for the nine
months  ended  September  30,  2004 as compared with net cash flows generated by
operating  activities  of  134,142  for the same period in 2003. The increase in
cash  used  in operations was primarily attributable to the prepaid expenses for
the  period.

     There were no cash flows from investing activities and financing activities
in  both  nine-months  periods  ended  September  30,  2004  and  2003.

     Overall, we have funded our cash needs from inception through September 30,
2004  with  a  series  of  debt  and  equity  transactions, primarily with Duane
Bennett,  our  former  President  and  majority stockholder. If we are unable to
receive  additional  cash  from our majority stockholder, we may need to rely on
financing  from  outside sources through debt or equity transactions. Failure to
obtain  such  financing  could  have a material adverse effect on operations and
financial  condition.

     As  discussed in this report, our independent auditors have expressed doubt
as  to  our  ability  to continue as a going concern. Our continued existence is
dependent  upon  our  ability  to  resolve  our business and liquidity problems,
principally  through  raising  additional  capital and increasing our sales. Our
plans  with  regard to this matter are to seek additional capital for operations
through  either  debt  or  equity  and/or  enact  a  business  combination.

ITEM  3.  QUANTITATIVE  AND  QUALITATIVE  DISCLOSURES  ABOUT  MARKET  RISK

     We  do  not  have  any  material  risk  with  respect to changes in foreign
currency exchange rates, commodities prices or interest rates. We do not believe
that  we  have  any  other  relevant  market risk with respect to the categories
intended  to  be  discussed  in  this  item  of  this  report.

ITEM  4.  CONTROLS  AND  PROCEDURES

(a)  On September 30, 2004, we made an evaluation of our disclosure controls and
     procedures.  In  our  opinion,  the  disclosure controls and procedures are
     adequate  because  the  systems  of controls and procedures are designed to
     assure,  among  other  items,  that  1) recorded transactions are valid; 2)
     valid  transactions  are  recorded; and 3) transactions are recorded in the
     proper  period  in  a  timely  manner to produce financial statements which
     present  fairly  the  financial  condition,  results of operations and cash
     flows  for the respective periods being presented. Moreover, the evaluation
     did  not  reveal any significant deficiencies or material weaknesses in our
     disclosure  controls  and  procedures.

(b)  There have been no significant changes in our internal controls or in other
     factors  that  could  significantly  affect  these  controls since the last
     evaluation.


PART  II.  OTHER  INFORMATION
---------

Item  1.  Legal  Proceedings

None.

Item  2.  Changes  in  Securities

None.

Item  3.  Defaults  Upon  Senior  Securities

None.


Item  4.  Submission  of  Matters  to  a  Vote  of  Security  Holders

None.

Item  5.  Other  Information

     Pursuant  to  the  Letter  of Intent dated March 22, 2004 between and among
Xenicent,  Duane Bennett and Harbin Ping Chuan Yao Ye Gu Fen You Xian Gong Si, a
corporation  organized  and  existing under the laws of the Peoples' Republic of
China  ("Ping Chuan"), on June 22, 2004, the Company executed a plan of exchange
pursuant  to  which Xenicent agreed to issue 70,000,000 new investment shares of
common  stock  to  the  shareholders  of Ping Chuan in exchange for all of their
shares of capital stock of Ping Chuan.  As a result of the exchange transaction,
Ping  Chuan  became a wholly-owned subsidiary of the Company, and the Ping Chuan
shareholders  control  approximately 98% of the issued and outstanding shares of
the  Company.  As  part  of  the  transaction,  Xenicent  agreed  to  change its
corporate name to Pingchuan Pharmaceutical Inc. and stock ticker symbol prior to
the  Closing.

     On  July  28,  2004, Xenicent changed its name to Pingchuan Pharmaceutical,
Inc.  and  increased  its  authorized  shares of common stock from 50,000,000 to
150,000,000  by  filing Articles of Amendment with the Secretary of State of the
State  on North Carolina. In addition, on August 3, 2004, the NASDAQ awarded the
new  trading  symbol  of  "PGCN"  to  the  Pingchuan  Pharmaceutical,  Inc.

     On August 11, 2004, the exchange transaction was consummated and on October
25,  2004,  audited  financial  statements  of  Ping Chuan and proforma combined
financial statements were filed in an amendment of Current Report on Form 8-K/A.

Item  6.  Exhibits  and  Reports  on  Form  8-K

(a)  Exhibits

3.   Articles  of  Incorporation  with amendments and bylaws are incorporated by
     reference  from  Exhibit  No.  1  of  Form SB-2, as amended, filed with the
     Commission  on  or  about  April  2001.
31.1 Certifications  of  CEO  pursuant  to  Section  302
31.2 Certifications  of  CFO pursuant to Section 302 (Included in Item No. 31.1)
32.1 Section  1350  Certifications  of  CEO
32.2 Section  1350  Certifications  of  CFO

(b)  Reports  on  Form  8-K

     An  amendment of Current Report on Form 8-K/A was filed with the Commission
on October 25, 2004, and is incorporated by reference herein. It reports audited
financial  statements  for  the  years  ended December 30, 2003 and 2002 of Ping
Chuan  and  pro  forma  combined  financial  statements.



                                   SIGNATURES
                                   ----------

Pursuant  to  the  requirements  of  the  Securities  Exchange  Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned,  thereunto  duly  authorized.



                                   PINGCHUAN  PHARMACEUTICAL,  INC.
                                   --------------------------------
                                  (Registrant)




                                   /S/  Zhanwu  Hu,  President
Date:  November  19,  2004         ---------------------------
                                   Zhanwu  Hu,  President